Jazz, Hikma, class plaintiffs get preliminary settlement nod in US Xyrem antitrust case
Jazz Pharmaceuticals, Hikma Pharmaceuticals and a class of indirect purchaser plaintiffs got preliminary settlement approval from a California federal judge today for overlapping claims alleging the defendants engaged in a pay-for-delay...To view the full article, register now.
Already a subscriber? Click here to view full article